The Standing Committee on Health (HESA) of the House of Commons met on Thursday, April 27, 2023, to begin its study of the Patented Medicine Prices Review Board (PMPRB). The Committee first heard from the Minister of Health, the Honourable Jean-Yves Duclos. The Minister’s appearance was followed by witnesses from the Department of Health and the Department of Justice, as well as Mélanie Bourassa Forcier, Professor at the University of Sherbrooke and the former Acting Chair of the PMPRB.
The Committee will reconvene on May 2, 2023, to hear from Matthew Herder, Associate Professor at Dalhousie University and former board member of the PMPRB, as well as the current Executive Director of the PMPRB, Douglas Clark.
Should you have any questions, please do not hesitate to contact a member of the Life Sciences Regulatory & Compliance group.
The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
Related Publications & Articles
-
Canada’s Drug Agency seeks input on HTA methods guide and also announces new coalition to improve medication use
HTA Methods Guide – On November 28, 2024, Canada’s Drug Agency (CDA) launched a consultation on its first-ever methods guide.Read More -
2023-2024 Pan-Canadian Pharmaceutical Alliance impact report
On November 22, 2024, the pan-Canadian Pharmaceutical Alliance (pCPA) released its 2023-2024 impact report.Read More -
PMPRB releases new Draft Guidelines for comment
Following its Phase 2 Consultations, on December 19, 2025, the Patented Medicine Prices Review Board released its new Draft Guidelines and accompanying Overview.Read More